Alerta

Serum-free culture medium and culture method for culturing NK92 and Car-NK92 cells in vitro

Absstract of: CN122405546A

The invention discloses a serum-free culture medium for culturing NK92 and Car-NK92 cells in vitro and a culture method. According to the serum-free culture medium, an IMDM culture medium and a DMEM/F12 mixed culture medium are used as basic culture mediums, and recombinant human cell factors, recombinant human insulin, essential amino acid compounds, vitamin supplements, trace element additives, lipid mixtures and antioxidants are added. The invention further discloses an application of the serum-free culture medium in culture of NK92 and Car-NK92 cells. The serum-free culture medium disclosed by the invention does not contain animal-derived components, has definite and controllable components, can remarkably promote the growth and proliferation of NK92 and CAR-NK92 cells, enhance the killing activity of the NK92 and CAR-NK92 cells and maintain a good biological function, is suitable for large-scale preparation of clinical-grade NK92 and CAR-NK92 cells, and can be applied to cell therapy, in-vitro killing experiments, anti-tumor drug screening and the like.

Intelligent glucometer with automatic calibration function and calibration method thereof

Absstract of: CN122409773A

The embodiment of the invention provides an intelligent glucometer with an automatic calibration function, which comprises a shell, a display screen and a test paper socket which are arranged on the shell, and a detection module which is arranged in the shell and is used for collecting an initial electrochemical signal generated by the reaction of a blood sample and a test paper reagent when test paper is inserted into the test paper socket and the blood sample is dropped into the test paper socket; the environment monitoring module is used for monitoring the current environment temperature in real time and collecting environment compensation parameters influencing the blood glucose detection accuracy; the storage module is used for storing a preset standard calibration curve and a dynamic compensation algorithm model; the automatic calibration module is connected with the detection module, the environment monitoring module and the storage module, and the automatic calibration module is used for receiving the initial electrochemical signals and the environment compensation parameters and conducting correction calculation on the initial electrochemical signals according to a dynamic compensation algorithm model to generate calibrated blood glucose values; and the display module is used for outputting the calibrated blood glucose value to a display screen for displaying.

Pollution exposure driven glycometabolism stratification method and system

Absstract of: CN122417420A

The invention relates to the technical field of big data processing, in particular to a pollution exposure driven glycometabolism layering method and system, and the method comprises the steps: obtaining air pollution monitoring data, meteorological data, space-time activity data, glycometabolism monitoring data and genetic data; reconstructing an individual pollution exposure process and determining an individual pollution exposure event; constructing an individual glucose metabolism baseline and determining a glucose metabolism offset; the glycometabolism toughness state is estimated in combination with genetic data; and determining a glycometabolism layering result according to the glycometabolism toughness state and a preset pollution scene. According to the method, the individual pertinence and the dynamic recognition capability of glycometabolism stratification can be improved.

SYSTEM, METHOD, AND COMPUTER READABLE MEDIUM FOR CGM-BASED OGTT REPLACEMENT DIAGNOSIS TEST

Absstract of: US20260204418A1

0000 Embodiments relate to a database management system for efficient physiological diagnosis of a specified physiological disorder. The system includes a physical data store containing glucose measurement data and a representation for a classification of the glucose measurement data. The glucose measurement data is associated with controlled glycemic-response consumption activity, the representation being indication that a glucose measurement trace is associated of a specified physiological disorder or is indicative of the specified physiological disorder, or is a surrogate of an existing metabolic test, e.g. OGTT. A processor receives a new glucose measurement possibly associated with controlled glycemic-response consumption activity, and classifies the newly received glucose measurement trace with the representation based either on a disease- or test-specific classifier or based on a matched similarity metric, and ascribes a clinical recommendation or assessment based on the representation of the classified newly received glucose measurement trace.

WEARABLE DUAL CLOSED-LOOP INSULIN DELIVERY SYSTEMS FOR PRECISION DIABETES MANAGEMENT

Absstract of: US20260199601A1

0000 A wearable dual closed-loop insulin delivery system is provided that integrates both a chemical closed-loop and an electronic closed-loop for precise glycemic control. The system includes a continuous glucose monitor (CGM) configured to obtain real-time blood glucose concentrations of a subject, and a glucose-responsive insulin (GRI) delivery device containing a GRI formulation that autonomously modulates its insulin-release rate in response to the subject's glucose levels, thereby forming a chemical closed-loop. The system further includes a controller having one or more computer processors executing a machine-learning adaptive glucose forecasting model with an Encoder-Decoder architecture. The model receives real-time glucose measurements from the CGM, predicts glycemia dynamics for at least a time period (i.e., 30 minute) future interval, and generates dosing-control signals to adjust both insulin-dosing amount and timing, forming an electronic closed-loop. The controller is operatively connected to the CGM and the GRI delivery device, enabling predictive, automated insulin regulation.

GLUCOSE MONITORING

Absstract of: US20260198807A1

0000 A light source is tuned to a range of wavelengths selected for relatively high absorption by glucose, while an optical sensor uses a complementary filter that selectively absorbs in the same spectrum. This optical channel, in combination with a separate, unfiltered reference optical channel, supports a calculation of glucose concentration in target tissue based on a ratiometric comparison of measured light intensities. In embodiments, quantum dots or other techniques can be used to tune the optical spectrum of a light source, while glucose or a similarly absorbing material can be embedded in an optical potting material or the like to create a similarly tuned filter for a corresponding optical sensor. The supporting hardware may usefully be deployed in a wearable physiological monitor for continuous monitoring of glucose (or other target molecules) in the tissue of a user.

INSULIN PEN-TYPE SYRINGE REFRIGERATION CUP

Absstract of: US20260199610A1

0000 An insulin pen-type syringe refrigeration cup is provided, which is provided with an insulin pen cartridge. The insulin pen-type syringe refrigeration cup includes a refrigeration component, a cold conduction tube, a cup lid, and a cup body. The cold conduction tube defines a storage space that accommodates insulin pens, the storage space is also suitable for accommodating the insulin pen cartridge. A diameter of the cold conduction tube is 20 mm-50 mm. The cold conduction tube includes an avoidance groove. The cup lid is suitable for accommodating the refrigeration component. The cup body includes a cup wall and an insulation chamber. The cup lid can detachably seal the insulation chamber, and the refrigeration component keeps the insulation chamber in a low temperature state. The present disclosure significantly reduces the volume by limiting the size of the cold conduction tube and providing the avoidance groove.

GLUCOSE LEVEL INDICATOR MODEL WITH MODIFIED ERROR RATE

Absstract of: US20260198867A1

A system is described herein comprising at least one application running on one or more processors of a server, wherein the at least one application is communicatively coupled with one or more sensor devices and a remote mobile device, the one or more sensor devices configured to monitor real time biometric data of a subject, the one or more sensing devices configured to transmit the real time biometric data to the at least one application, the at least one application configured to extract feature data variables from the real time biometric data, apply a predictive model to the feature data variables to predict glucose levels of the subject over a future period of time, and communicate a signal to the mobile device when predicted glucose levels cross either an upper or lower threshold.

Smart Footwear, Insoles or Other Wearables with Electronically Read Sensing Membrane and Self-Identification of Left/Right Status

Absstract of: US20260198800A1

Wearable smart devices are disclosed that incorporate a unique means of detecting or measuring a substance of interest, for example to detect ammonia in the secreted foot sweat of a diabetic via incorporation of the sensing arrangement in a footwear article or insole. The setup employs the combination of a colour-changing sensing membrane responsive to the substance of interest, an optical sensor appropriately positioned to capture the membrane within its field of view, and an illumination means for illuminating the membrane to enable optical imaging thereof, from which a controller can then detect the colour of the membrane and determine the presence or measurement of the substance of interest. A left/right self-identification circuit is included in each wearable smart device to enable a cooperative pair of such devices, worn on different bilateral appendages, to self-identify their left/right designation to the external device that receives the outputted signals from the wearables.

INSULIN FRAGMENT TAG AND PHARMACEUTICAL COMPOSITION

Absstract of: US20260201010A1

The present invention addresses the problem of providing a polypeptide tag that is capable of delivering peptides or polypeptides to neurons. The problem is solved by an insulin fragment tag for delivering interested molecules to neurons, the insulin fragment tag comprising a polypeptide including an amino acid sequence that has at least 90% identity with the amino acid sequence of at least one chain selected from an insulin A-chain and an insulin B-chain, and the insulin fragment tag having binding capacity insulin receptors.

METHODS OF DOSING AND ADMINISTRATION OF ENGINEERED ISLET CELLS

Absstract of: WO2026151664A1

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and/or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

METHOD OF DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MONOHORMONAL CELLS

Absstract of: US20260201339A1

0000 Compositions and methods are provided for generation of a population of monohormonal from human pluripotent cells. The method comprises sequentially exposing pluripotent stem cells to medium comprising CHIR99021 and Activin A; medium comprising Activin A; medium comprising FGF7; medium comprising retinoic acid, LDN193189, SANT1; medium comprising retinoic acid, LDN193189, SANT1, EGF and FGF2; and differentiation medium. A majority of cells in the population are monohormonal cells produce insulin, but not glucagon, somatostatin or ghrelin.

BLOOD GLUCOSE MANAGEMENT METHOD, USER INTERFACE, AND RELATED APPARATUS

Absstract of: US20260204390A1

0000 A blood glucose management method, a user interface, and a related apparatus are provided. According to one example of the blood glucose management method, a first meal time can be determined based on historical blood glucose values of a user; a second meal time can be determined based on one or more of the following: a meal time input by the user, a hand movement of the user, and a heart rate of the user; and a third meal time can be determined based on the first meal time and the second meal time, where the third meal time is used to evaluate a blood glucose health status of the user.

METHOD OF INDUCING UMBILICAL CORD MESENCHYMAL STEM CELLS TO DIFFERENTIATE INSULIN-LIKE CELLS AND AN APPLICATION THEREOF

Absstract of: US20260201338A1

A method of inducing umbilical cord mesenchymal stem cells to differentiate insulin-like cells and an application thereof, the invention carries out reasonable culture of purified umbilical cord mesenchymal stem cells by adopting culture medium having different substances, and can efficiently and stably induce them to differentiate into insulin-like cells, and the percentage of insulin-positive cells can reach 80%. The cell preparation prepared after induction of umbilical cord mesenchymal stem cells of the invention can be used for the treatment of clinical diabetic patients with high therapeutic efficacy.

INDUCTIVE CHARGING OF AN INFUSION PUMP

Absstract of: US20260199590A1

A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.

MACHINE LEARNING MODELS FOR DETECTING OUTLIERS AND ERRONEOUS SENSOR USE CONDITIONS AND CORRECTING, BLANKING, OR TERMINATING GLUCOSE SENSORS

Nº publicación: US20260204414A1 16/07/2026

Applicant:

MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc.

Absstract of: US20260204414A1

Techniques disclosed herein relate to sensor data. In some embodiments, the techniques may involve obtaining sensor data. The techniques may further involve applying, to the sensor data, a machine learning model trained to identify outlier measurements. The techniques may further involve determining, based on output from the machine learning model, that the sensor data corresponds to an outlier measurement. The techniques may further involve blanking the sensor data based on the output.